Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Michael H. Davidson and Evan Stein.

 
Connection Strength
 
 
 
0.844
 
  1. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007 Jul; 29(7):1354-67.
    View in: PubMed
    Score: 0.095
  2. Davidson MH, Bays HE, Stein E, Maki KC, Shalwitz RA, Doyle R. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. Clin Cardiol. 2006 Jun; 29(6):268-73.
    View in: PubMed
    Score: 0.088
  3. Davidson MH, Bays H, Rhyne J, Stein E, Rotenberg K, Doyle R. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2005 Jun; 27(6):715-27.
    View in: PubMed
    Score: 0.082
  4. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, März W, Reckless JP, Stein EA. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003 Mar 10; 163(5):553-64.
    View in: PubMed
    Score: 0.070
  5. Davidson M, Ma P, Stein EA, Gotto AM, Raza A, Chitra R, Hutchinson H. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002 Feb 01; 89(3):268-75.
    View in: PubMed
    Score: 0.065
  6. Davidson MH, Stein EA, Hunninghake DB, Ose L, Dujovne CA, Insull W, Bertolami M, Weiss SR, Kastelein JJ, Scott RS, Campodónico S, Escobar ID, Schrott HG, Bays H, Stepanavage ME, Wu M, Tate AC, Melino MR, Kush D, Mercuri M, Mitchel YB. Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2000 Oct; 10(5):253-62.
    View in: PubMed
    Score: 0.060
  7. Stein E, Plotkin D, Bays H, Davidson M, Dujovne C, Korenman S, Stepanavage M, Mercuri M. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol. 2000 Aug 15; 86(4):406-11.
    View in: PubMed
    Score: 0.059
  8. Stein EA, Illingworth DR, Kwiterovich PO, Liacouras CA, Siimes MA, Jacobson MS, Brewster TG, Hopkins P, Davidson M, Graham K, Arensman F, Knopp RH, DuJovne C, Williams CL, Isaacsohn JL, Jacobsen CA, Laskarzewski PM, Ames S, Gormley GJ. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 1999 Jan 13; 281(2):137-44.
    View in: PubMed
    Score: 0.053
  9. Stein EA, Davidson MH, Dobs AS, Schrott H, Dujovne CA, Bays H, Weiss SR, Melino MR, Stepanavage ME, Mitchel YB. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol. 1998 Aug 01; 82(3):311-6.
    View in: PubMed
    Score: 0.051
  10. Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black D. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol. 1997 Jun 01; 79(11):1475-81.
    View in: PubMed
    Score: 0.047
  11. Davidson MH, Stein EA, Dujovne CA, Hunninghake DB, Weiss SR, Knopp RH, Illingworth DR, Mitchel YB, Melino MR, Zupkis RV, Dobrinska MR, Amin RD, Tobert JA. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol. 1997 Jan 01; 79(1):38-42.
    View in: PubMed
    Score: 0.046
  12. Meuwese MC, de Groot E, Duivenvoorden R, Trip MD, Ose L, Maritz FJ, Basart DC, Kastelein JJ, Habib R, Davidson MH, Zwinderman AH, Schwocho LR, Stein EA. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA. 2009 Mar 18; 301(11):1131-9.
    View in: PubMed
    Score: 0.027
  13. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 Jul 15; 92(2):152-60.
    View in: PubMed
    Score: 0.018
  14. Isaacsohn J, Hunninghake D, Schrott H, Dujovne CA, Knopp R, Weiss SR, Bays H, Crouse JR, Davidson MH, Keilson LM, McKenney J, Korenman SG, Dobs AS, Stein E, Krauss RM, Maccubbin D, Cho M, Plotkin DJ, Mitchel YB. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol. 2003 Jan; 26(1):18-24.
    View in: PubMed
    Score: 0.017
  15. Dujovne CA, Bays H, Davidson MH, Knopp R, Hunninghake DB, Stein EA, Goldberg AC, Jones P, Lipka LJ, Cuffie-Jackson C. Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. J Clin Pharmacol. 2001 Jan; 41(1):70-8.
    View in: PubMed
    Score: 0.015
  16. Dobs AS, Schrott H, Davidson MH, Bays H, Stein EA, Kush D, Wu M, Mitchel Y, Illingworth RD. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism. 2000 Sep; 49(9):1234-8.
    View in: PubMed
    Score: 0.015
  17. Ose L, Davidson MH, Stein EA, Kastelein JJ, Scott RS, Hunninghake DB, Campodonico S, Insull W, Escobar ID, Schrott HG, Stepanavage ME, Wu M, Tate AC, Melino MR, Mercuri M, Mitchel YB. Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. Clin Cardiol. 2000 Jan; 23(1):39-46.
    View in: PubMed
    Score: 0.014
  18. Heinonen TM, Stein E, Weiss SR, McKenney JM, Davidson M, Shurzinske L, Black DM. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther. 1996 Sep-Oct; 18(5):853-63.
    View in: PubMed
    Score: 0.011
  19. Schrott HG, Stein EA, Dujovne CA, Davidson MH, Goris GB, Oliphant TH, Phillips JC, Shawaryn GG. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol. 1995 Jan 01; 75(1):34-9.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.